Dean Margeson

2.2k total citations · 1 hit paper
9 papers, 951 citations indexed

About

Dean Margeson is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Dean Margeson has authored 9 papers receiving a total of 951 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 4 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Dean Margeson's work include Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Cancer Genomics and Diagnostics (2 papers). Dean Margeson is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Cancer Genomics and Diagnostics (2 papers). Dean Margeson collaborates with scholars based in United States and Germany. Dean Margeson's co-authors include Michael A. Caligiuri, Susan P. Whitman, Guido Marcucci, Clara D. Bloomfield, Andrew J. Carroll, Maria R. Baer, Krzysztof Mrózek, Richard A. Larson, Michael D. Radmacher and Heiko Becker and has published in prestigious journals such as Journal of Clinical Oncology and Blood.

In The Last Decade

Dean Margeson

9 papers receiving 934 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

2010 548 citations Guido Marcucci, Kati Maharry et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dean Margeson United States	5	711	552	289	283	167	9	951
Yue-Zhong Wu United States	7	770 1.1×	670 1.2×	311 1.1×	396 1.4×	172 1.0×	16	1.1k
Kelsi B. Holland United States	4	548 0.8×	433 0.8×	232 0.8×	252 0.9×	100 0.6×	7	745
Marta Pratcorona Spain	14	791 1.1×	572 1.0×	269 0.9×	193 0.7×	214 1.3×	29	1.0k
Heinz-A. Horst Germany	6	443 0.6×	360 0.7×	253 0.9×	230 0.8×	135 0.8×	6	791
Jessica Kohlschmidt United States	19	765 1.1×	574 1.0×	239 0.8×	313 1.1×	198 1.2×	50	1.1k
Dong‐ming Yao China	20	684 1.0×	786 1.4×	201 0.7×	315 1.1×	69 0.4×	61	1.0k
Marion Massop Netherlands	4	650 0.9×	917 1.7×	278 1.0×	168 0.6×	68 0.4×	6	1.2k
Kiyotaka Kashima Japan	8	992 1.4×	499 0.9×	386 1.3×	87 0.3×	274 1.6×	14	1.2k
Mauro Nanni Italy	16	456 0.6×	402 0.7×	294 1.0×	113 0.4×	112 0.7×	43	804
Maria‐Cristina Sauerland Germany	8	1.1k 1.5×	688 1.2×	260 0.9×	147 0.5×	294 1.8×	10	1.2k

Countries citing papers authored by Dean Margeson

Since Specialization

Citations

This map shows the geographic impact of Dean Margeson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Margeson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Margeson more than expected).

Fields of papers citing papers by Dean Margeson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Margeson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Margeson. The network helps show where Dean Margeson may publish in the future.

Co-authorship network of co-authors of Dean Margeson

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Margeson. A scholar is included among the top collaborators of Dean Margeson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Margeson. Dean Margeson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Becker, Heiko, Kati Maharry, Michael D. Radmacher, et al.. (2010). Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. Blood. 116(21). 577–577. 1 indexed citations

Schwind, Sebastian, Guido Marcucci, Kati Maharry, et al.. (2010). BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116(25). 5660–5669. 77 indexed citations

Marcucci, Guido, Kati Maharry, Yue-Zhong Wu, et al.. (2010). IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 28(14). 2348–2355. 548 indexed citations breakdown →

Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 28(4). 596–604. 241 indexed citations

Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.. Blood. 114(22). 326–326. 19 indexed citations

Whitman, Susan P., Kati Maharry, Michael D. Radmacher, et al.. (2009). Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.. Blood. 114(22). 1579–1579. 4 indexed citations

Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). Journal of Clinical Oncology. 27(15_suppl). 7000–7000. 3 indexed citations

Mrózek, Krzysztof, Kelsi B. Holland, Mark J. Pettenati, et al.. (2009). Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study.. Blood. 114(22). 2602–2602. 2 indexed citations

Whitman, Susan P., Björn Hackanson, Sandya Liyanarachchi, et al.. (2008). DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 112(5). 2013–2016. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact